<DOC>
	<DOCNO>NCT00344279</DOCNO>
	<brief_summary>This study , sponsor National Institutes Health Tuberculosis Research Centre YRG-Care Chennai , India , examine treatment lymphatic filariasis HIV-infected patient influence amount HIV virus blood progression HIV infection AIDS . Filarial infection common Chennai , important understand whether treatment filariasis affect course HIV disease . The information gain study could use modify treatment people HIV filarial infection . Patients 18 year age old receive treatment HIV infection Government Hospital HIV clinic YRG-Care may eligible study . Two group patient recruit - patient HIV filarial infection , patient HIV infection alone , without filariasis . Candidates screen medical history review medical record , physical examination , blood stool test . Women urine pregnancy test . Within one month screening , participant receive single dose diethylcarbamazine albendazole , drug regimen commonly use treat filarial infection . Patients follow closely first 2 week treatment check side effect . They see 1 , 3 , 6 12 month treatment dose physical examination blood test .</brief_summary>
	<brief_title>Changes HIV Viral Load Patients Undergoing Treatment Filariasis</brief_title>
	<detailed_description>To determine effect pre-existing filarial infection treatment viral burden clinical parameter patient infected HIV , study aim follow plasma HIV load , CD4 count , clinical parameter population HIV-infected individual co-infected Wuchereria bancrofti , prior treatment filarial infection . The study individual draw patient cohort follow HIV Clinic Government General Hospital Tuberculosis Research Centre , Chennai , India , YRG-Care ( Chennai , India ) , area endemic lymphatic filariasis ( LF ) prevalence HIV infection general population 7 % . These patient adult age , male female , come state Tamil Nadu Andhra Pradhesh . Having establish part previous protocol ( 01-I-N022 ) HIV/filarial coprevalence 6-10 % base W. bancrofti circulate antigen detection HIV-positive -negative individual , patient co-infection HIV LF diagnose pair two HIV-positive ( filarial antigen negative ) clinic control match age , gender , viral load antiretroviral therapy CD4 count . All effort make connect study participant program antiretroviral distribution . Within month baseline clinical evaluation , patient control receive single dose combination diethylcarbamazine/albendazole ( drug combination give part national campaign eliminate LF ) follow viral load , CD4 count clinical examination one week , well 1 , 3 , 6 12 month administration . By assess change , influence co-existing filarial infection plasma HIV viral load , CD4 count clinical course determine . At end study period , participant re-assessed filarial antibody antigen ensure absence parasite . Any patient evidence ongoing filarial infection W. bancrofti re-treated DEC/albendazole .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Filariasis</mesh_term>
	<criteria>INCLUSION CRITERIA : Greater 18 year age . Ability give inform consent HIV positive If antiretrovirals treatment opportunistic infection , stable maintenance period least 2 month Male female , provide woman neither pregnant breastfeeding Willingness adhere test schedule protocol provide small amount blood ( 5 ml ) multiple occasion Willingness treat DEC/albendazole Willingness , female , test pregnancy inform test result Willingness sample store future research EXCLUSION CRITERIA : Acutely ill time enrollment study i.e . newly diagnose opportunistic infection yet stabilize treatment regime . Hemoglobin le 9 g/l woman le 10 g/l men AST , ALT great 5 time normal Evidence acute HIV infection ( acute antiretroviral syndrome ) Active tuberculosis know tuberculosis A true allergy DEC albendazole At discretion investigator felt someone appropriate study ( i.e . know active drug use , patient history chronic noncompliance clinic visit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 31, 2012</verification_date>
	<keyword>Coinfection</keyword>
	<keyword>AIDS</keyword>
	<keyword>Lymphatic Filariasis</keyword>
	<keyword>Diethylcarbamazine ( DEC )</keyword>
	<keyword>Albendazole</keyword>
</DOC>